Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Stahel, R A ^a,c   Weder, W ^a,c   Felip, E ^b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; DOXORUBICIN; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED;

ARTICLE; ASBESTOSIS; CANCER INCIDENCE; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; EVIDENCE BASED MEDICINE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MONOTHERAPY; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; THORACOSCOPY; THORAX PAIN; TREATMENT RESPONSE; INCIDENCE; MESOTHELIOMA; PATHOLOGY; PLEURA TUMOR;

FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS;

EID: 45149084771     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn083     Document Type: Article

References (15)

1. Peto J, Decarli A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999; 86: 1970-1971.
2. Pelucchi C, Malvezzi M, La Vecchia C et al. The mesothelioma epidemic in Western Europe: An update. Br J Cancer 2004; 90: 1022-1024.
3. Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999; 17: 54-63.
5. Waller DA. The role of surgery in diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Oncol 2003; 15: 139-143.
6. Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-1202.
7. Rice DC, Smythe WR, Liao Z et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007; 69: 350-357.
8. ORourke N, Garcia JC, Paul J et al. A randomized controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22.
9. Ellis P, Davies AM, Evans WK et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and practice guideline. J Thorac Oncol 2006; 1: 591-601.
10. Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant mesothelioma. Ann Oncol 2005; 16: 345-351.
11. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
12. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889.
13. Bottomley A, Gaafar R, Manegold C et al. Short-term treatment-related symptoms and quality of life: Results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and Natioanl Cancer Institute, Canada. Intergroup Study. J Clin Oncol 2006; 24: 1435-1442.
14. Jassem J, Ramlau R, Santoro A et al. A randomised phase III trial comparing pemetrexed plus best supportive care vs best supportive care in previously treated patients with advanced malignant mesothelioma. Ann Oncol 2006; 17 (Suppl 9): Abstr 7150.
15. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-260.